Rapport Therapeutics, Inc. (RAPP) has received a new Buy rating, initiated by H.C. Wainwright analyst, Douglas Tsao.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight the potential of Rapport Therapeutics, Inc.’s RAP-219 in addressing unmet needs in epilepsy treatment. The drug offers a unique clinical profile with strong seizure reduction capabilities, a distinctive safety profile, and an extended duration of effect that could reduce the risk of breakthrough seizures. RAP-219’s mechanism, which targets the TARPγ8 receptor accessory protein, allows for precise targeting within the central nervous system, potentially minimizing motor side effects associated with similar treatments.
Additionally, RAP-219’s potency and extended half-life set it apart from existing anti-seizure medications, making it a promising candidate for inclusion in focal onset seizure drug regimens. The development of a long-acting injectable formulation further enhances its appeal, with potential sales projections exceeding $1 billion. Upcoming Phase 2 data is expected to provide further evidence of RAP-219’s differentiated profile, supporting Tsao’s optimistic outlook and the $31 price target for Rapport Therapeutics.
Tsao covers the Healthcare sector, focusing on stocks such as Argenx Se, Crinetics Pharmaceuticals, and Disc Medicine. According to TipRanks, Tsao has an average return of 11.3% and a 45.03% success rate on recommended stocks.